JLE

Epileptic Disorders

MENU

Comparison of twice- and three times daily tiagabine for the adjunctive treatment of partial seizures in refractory patients with epilepsy: an open label, randomised, parallel-group study Volume 3, issue 2, June 2001

1. Leach JP, Brodie MJ. Tiagabine (Drug Profile). Lancet 1998; 351: 203-7.

2. Sander JWAS, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg. Psychiatry 1996; 6: 433-43.

3. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996; 334: 1583-90.

4. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: systematic review or their efficacy and tolerability. Epilepsia 1997; 38: 859-80.

5. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995; 36: 612-26.

6. Schachter SC. Antiepileptic drug therapy: general treatment principles and application for special patient populations. Epilepsia 1999; 40 (suppl 9): S20-5.

7. Brodie MJ. Tiagabine in the management of epilepsy. Epilepsia 1997; 38 (suppl 2): S23-7.

8. Gustavson LE, Mengel HB. Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor in healthy subjects after single and multiple doses. Epilepsia 1995; 36: 605-11.

9. So EL, Wolff D, Graves N, Leppik IE, Cascino GD, Pixton GC, Gustavson LE. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res 1995; 22: 221-6.

10. Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsia 1995; 36 (suppl 6): S14-21.

11. Leppik IE. Tiagabine: the safety landscape. Epilepsia 1995; 36 (suppl 6): S10-3.

12. Sveinbjornsdottir S, Sander JWAS, Patsalos PN, Upton D. Thompson PJ, Duncan JS. Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 1994; 3: 29-35.

13. Kalviainen R, Aikia M, Mervaal E, Saukkonen AM, Pitkanen A, Riekinen PJ. Long-term cognitive and EEG effects of tiagabine in drug resistant partial epilepsy. Epilepsy Res 1996; 25: 291-7.

14. Loiseau P. Review of controlled trials of Gabitril (tiagabine): a clinician's viewpoint. Epilepsia 1999; 40 (suppl 9): S14-9.

15. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981; 22: 489-501.

16. Allison PD. Survival analysis using the SAS system. A practical guide. SAS Institute Inc 1995.

17. Cytel Software Corporation. Log Xact User Manual 1993.

18. Adkins JC, Noble S. Tiagabine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998; 55: 437-60.

19. Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, Karim RM and the Topiramate YD Study Group. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996; 46: 1684-90.

20. Schmidt D, Jacob R, Loiseau P, Deisenhammer E, Klinger D, Despland A, Egli M, Bauer G, Stenzel E, Blankenhorn V. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993; 15: 67-73.

21. Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures; a double-blind, placebo-controlled study. Epilepsia 1994; 35: 795-801.

22. Willmore LJ, Shu V, Wallin B and the M88-194 Study Group. Efficacy and safety of add-on divalproex sodium in the treatment of complex partial seizures. Neurology 1996; 46: 49-53.

23. Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, Lineberry CG. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. US Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993; 43: 2284-91.

24. Schmidt D, Gram L, Brodie M, Kramer G, Perucca E, Kalviainen R, Elger CE. Tiagabine in the treatment of epilepsy - a clinical review with a guide for the prescribing physician. Epilepsy Res 2000; 41: 245-51.